Literature DB >> 19076134

Outcome of radical prostatectomy for incidental carcinoma of the prostate.

Sebastian Melchior1, Boris Hadaschik, Sebastian Thüroff, Christian Thomas, Rolf Gillitzer, Joachim Thüroff.   

Abstract

OBJECTIVE To evaluate a contemporary series of patients with incidental prostate cancer detected by transurethral resection of the prostate (TURP) and undergoing radical prostatectomy (RP). PATIENTS AND METHODS Between 1998 and 2004, 1931 patients had TURP for obstructive voiding symptoms and suspected BPH. Incidental prostate cancer was found in 104 (5.4%); 26 of these patients had a RP. The pathological staging and treatment of these patients were reviewed retrospectively and the follow-up results obtained. RESULTS Of the 26 patients who had RP, 17 had T1a and nine had T1b carcinoma of the prostate. After RP, six (35%) in the T1a group had no residual tumour (pT0) and 11 (65%) had pT2 cancer; the respective incidence in those with T1b was two and seven, with no pT3 disease in either group. The preoperative Gleason grading did not correspond well with that after RP; 30% of the patients had upgraded Gleason scores and 42% showed either downgrading or no residual tumour, with 81% having Gleason scores of <7. After a median follow-up of 47 months, one patient is receiving hormonal therapy because of biochemical relapse. Conclusion Subsequent to stringent PSA testing and prostate biopsy when indicated, the rate of incidental prostate cancer is low. Furthermore, substantially many patients will harbour either no residual cancer or tumours with favourable characteristics in their RP specimens. However, there is currently no possibility to reliably predict the absence of aggressive prostate cancer after TURP, and thus safely recommend observation instead of further therapy. Therefore, patients with incidental prostate cancer need to be counselled individually. The decision 'treatment or no treatment' should be determined by the patients' age and life-expectancy, tumour aggressiveness in the TURP specimen and the prostate-specific antigen level after TURP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19076134     DOI: 10.1111/j.1464-410X.2008.08279.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

1.  HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis.

Authors:  Bernd Rosenhammer; Eva M Lausenmeyer; Roman Mayr; Maximilian Burger; Christian Eichelberg
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

2.  Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate.

Authors:  Satoshi Otsubo; Akira Yokomizo; Osamu Mochida; Masaki Shiota; Katsunori Tatsugami; Junich Inokuchi; Seiji Naito
Journal:  World J Urol       Date:  2014-05-08       Impact factor: 4.226

3.  An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent.

Authors:  Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Henrik Møller; Tim Oliver; Victor Reuter; Peter T Scardino; Jack Cuzick; Daniel M Berney
Journal:  Mod Pathol       Date:  2010-09-10       Impact factor: 7.842

4.  "Finding the needle in a haystack": oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP).

Authors:  Annika Herlemann; Kerstin Wegner; Alexander Roosen; Alexander Buchner; Philipp Weinhold; Alexander Bachmann; Christian G Stief; Christian Gratzke; Giuseppe Magistro
Journal:  World J Urol       Date:  2017-05-17       Impact factor: 4.226

5.  MUC1 expression in incidental prostate cancer predicts staging and grading on the subsequent radical prostatectomy.

Authors:  Sven Gunia; Matthias May; Stefan Koch; Manfred Dietel; Andreas Erbersdobler
Journal:  Pathol Oncol Res       Date:  2009-11-27       Impact factor: 3.201

6.  An Advanced but Traditional Technique of Transurethral Resection of the Prostate in Order not to Overlook Stage T1 Prostate Cancer.

Authors:  Masaru Morita; Takeshi Matsuura
Journal:  Curr Urol       Date:  2012-04-30

7.  Three-dimensional proton magnetic resonance spectroscopy and diffusion-weighted imaging in the differentiation of incidental prostate carcinoma from benign prostate hyperplasia.

Authors:  Xue-Qin Zhang; Xiang-Rong Yu; Zhong-Li Du; Xiao-Fen Miao; Jian Lu; Quan Zhou
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

8.  Optimal Monitoring of Prostate-Specific Antigen Detects Prostate Cancer at the Localized Stage after Photoselective Vaporization for Benign Prostatic Hyperplasia.

Authors:  Jun Furusawa; Yasushi Yamada; Norihito Soga; Isao Kuromatsu
Journal:  Curr Urol       Date:  2019-05-10

9.  Preoperative clinical factors for diagnosis of incidental prostate cancer in the era of tissue-ablative surgery for benign prostatic hyperplasia: a korean multi-center review.

Authors:  Changhee Yoo; Cheol Young Oh; Se Joong Kim; Sun Il Kim; Young Sig Kim; Jong Yeon Park; Do Hwan Seong; Yun Seob Song; Won Jae Yang; Hyun Chul Chung; In Rae Cho; Sung Yong Cho; Sang Hyeon Cheon; Sungjoon Hong; Jin Seon Cho
Journal:  Korean J Urol       Date:  2012-06-19

10.  Preoperative parameters to predict incidental (T1a and T1b) prostate cancer.

Authors:  Hirofumi Sakamoto; Kazuhiro Matsumoto; Nozomi Hayakawa; Takahiro Maeda; Atsuko Sato; Akiharu Ninomiya; Kiyoshi Mukai; So Nakamura
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.